Primary and secondary hemostasis in patients with subclinical hypothyroidism: Effect of levothyroxine treatment
| Autor: | Pasquale Ambrosino, Roberta Lupoli, Anna Tortora, Matteo Nicola Dario Di Minno, Livia Barba, Alessandra Scaravilli, Giovanni Lupoli, Alessandro Di Minno, Gelsy Arianna Lupoli, Marianna Cacciapuoti |
|---|---|
| Přispěvatelé: | Lupoli, Roberta, Di Minno, Matteo Nicola Dario, Tortora, Anna, Scaravilli, Alessandra, Cacciapuoti, Marianna, Barba, Livia, Di Minno, Alessandro, Ambrosino, Pasquale, Lupoli, Gelsy Arianna, Lupoli, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Platelet Aggregation Endocrinology Diabetes and Metabolism Clinical Biochemistry Levothyroxine Context (language use) Biochemistry Follow-Up Studie Endocrinology Hypothyroidism Internal medicine medicine Humans Fibrinolysi Mean platelet volume Hemostatic function Prospective cohort study Hemostasis Asymptomatic Disease business.industry Fibrinolysis Medicine (all) Biochemistry (medical) Hemostasi Middle Aged Thyroxine Asymptomatic Diseases Female business Plasminogen activator Mean Platelet Volume Fibrinolytic agent Follow-Up Studies medicine.drug Human |
| Popis: | Subclinical hypothyroidism (SH) is associated with some abnormalities in primary and secondary hemostasis.The objective of the study was to evaluate changes in primary and secondary hemostasis induced by levothyroxine (L-T4) treatment in SH patients.This was a prospective cohort study with a 6-month follow-up.Outpatients were referred to "Federico II" University of Naples.Subjects with a SH without previous/ongoing L-T4 therapy participated in the study.Changes in major hemostatic/fibrinolytic variables and platelet reactivity [mean platelet volume (MPV), arachidonic acid (AA), or ADP concentrations inducing a ≥ 50% irreversible aggregation (AC-50%)] in SH patients before and after a 6-month L-T4 treatment.At baseline, 41 SH patients showed higher levels of factor VII activity (123.9 ± 20.4 vs 107.7 ± 12.2, P.001), plasminogen activator inhibitor-1 (33.6 ± 13.9 vs 22.5 ± 5.74, P.001) and tissue plasminogen activator (5.56 ± 2.22 vs 4.75 ± 1.61, P = .010), with lower levels of D-dimer (220.3 ± 67.1 vs 252.1 ± 72.4, P = .017) compared with healthy controls. SH patients also showed a higher MPV (9.92 ± 1.15 vs 8.9 ± 0.9, P.001) and AC-50% to AA (0.18 ± 0.12 vs 0.36 ± 0.10, P.001) and to ADP (1.5 ± 0.6 vs 1.9 ± 1.3, P = .024). After a 6-month L-T4 therapy, a reduction of factor VII activity (from 123.9 ± 20.4 to 102.6 ± 14.3, P.001), plasminogen activator inhibitor-1 (33.6 ± 13.9 to 19.4 ± 7.6, P.001), and tissue plasminogen activator (5.56 ± 2.22 to 1.91 ± 4:43, P = .002) was found in SH subjects, with a marginal increase in D-dimer (from 220.3 ± 67.1 to 245.2 ± 103.1, P = .053). AC-50% to AA (from 0.18 ± 0.12 to 0.54 ± 0.3, P.001) and to ADP (from 1.5 ± 0.6 to 1.86 ± 0.3, P = .042) were reduced, paralleled by a significant reduction of MPV (from 9.92 ± 1.15 to 9.10 ± 1.23, P = .016).SH patients exhibit a prothrombotic status, which is reverted by a 6-month L-T4 treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|